Literature DB >> 6800771

Thyrotropin-releasing hormone (TRH) selectively and rapidly stimulates phosphatidylinositol turnover in GH pituitary cells: a possible second step of TRH action.

C A Sutton, T F Martin.   

Abstract

TRH was found to rapidly influence 32PO4 incorporation into phospholipids of PRL-secreting GH pituitary cells. Analogs of TRH were found to exert similar effects, with potencies related to receptor-binding affinity. Additional PRL-releasing agents were also tested. Bombesin exerted a similar effect, whereas vasoactive intestinal polypeptide, 8-bromo cAMP, phosphodiesterase inhibitors, 50 mM K+, and scorpion venom toxin had no influence. Cationophore A23187 stimulated phospholipid labeling in a manner distinguishable from that of TRH. Chromatographic analysis showed the action of TRH to be restricted to the labeling of phosphatidylinositol and phosphatidic acid. Kinetic studies indicated a rapid influence of TRH on phosphatidylinositol breakdown, with subsequent accelerated 32PO4 incorporation into phosphatidylinositol and phosphatidic acid. These studied identified a rapid, receptor-mediated, cAMP-independent action of TRH on phospholipid metabolism. Similar effects of other hormones are believed to be involved in promoting cellular Ca2+ translocation. The rapid onset of the response reported here suggests that this event may play a role in mediating the PRL-releasing effects of TRH and bombesin in GH cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6800771     DOI: 10.1210/endo-110-4-1273

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  The interaction of benzodiazepines with thyrotropin-releasing hormone receptors on clonal pituitary cells.

Authors:  L A Joels; A H Drummond
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

2.  Regulation of GH3-cell function via adenosine A1 receptors. Inhibition of prolactin release, cyclic AMP production and inositol phosphate generation.

Authors:  T M Delahunty; M J Cronin; J Linden
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

3.  The interaction of lithium with thyrotropin-releasing hormone-stimulated lipid metabolism in GH3 pituitary tumour cells. Enhancement of stimulated 1,2-diacylglycerol formation.

Authors:  A H Drummond; C A Raeburn
Journal:  Biochem J       Date:  1984-11-15       Impact factor: 3.857

4.  Characterization of pituitary calcium-activated, phospholipid-dependent protein kinase: redistribution by gonadotropin-releasing hormone.

Authors:  Z Naor; J Zer; H Zakut; J Hermon
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

5.  Adenosine 3',5'-cyclic monophosphate-dependent release of prolactin from GH3 pituitary tumour cells. A quantitative analysis.

Authors:  S Guild; A H Drummond
Journal:  Biochem J       Date:  1983-12-15       Impact factor: 3.857

6.  Thyrotropin-releasing hormone mobilizes Ca2+ from endoplasmic reticulum and mitochondria of GH3 pituitary cells: characterization of cellular Ca2+ pools by a method based on digitonin permeabilization.

Authors:  S A Ronning; G A Heatley; T F Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

7.  Thyroliberin stimulates rapid hydrolysis of phosphatidylinositol 4,5-bisphosphate by a phosphodiesterase in rat mammotropic pituitary cells. Evidence for an early Ca2+-independent action.

Authors:  M J Rebecchi; M C Gershengorn
Journal:  Biochem J       Date:  1983-11-15       Impact factor: 3.857

8.  Regulation of GH3 pituitary tumour-cell adenylate cyclase activity by activators of protein kinase C.

Authors:  L A Quilliam; P R Dobson; B L Brown
Journal:  Biochem J       Date:  1989-09-15       Impact factor: 3.857

9.  Pharmacological and biochemical comparison of thyrotropin releasing hormone (TRH) and di-methyl proline-TRH on pituitary GH3 cells.

Authors:  A M McDermott; G P Wilkin; S L Dickinson
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.